Stem cells as therapeutic vehicles for the treatment of high-grade gliomas

Neuro-Oncology

Volumn 14, Issue 3, 2012, Pages 256-265

  Binello, Emanuela ^a   Germano, Isabelle M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cancer stem cells; cell based therapy; high grade glioma; stem cells

Indexed keywords

ALPHA INTERFERON; ANTIBODY; BETA INTERFERON; CYTOKINE; DOXYCYCLINE; FLUCYTOSINE; GANCICLOVIR; GELATINASE A; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 4; PHARMACEUTICAL VEHICLES AND ADDITIVES; PRODRUG; PROTEIN KINASE B; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BLOOD BRAIN BARRIER; CANCER SURGERY; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; EMBRYONIC STEM CELL; ETHICS; GLIOMA; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOGENICITY; MESENCHYMAL STEM CELL; NEURAL STEM CELL; NONHUMAN; PROGNOSIS; STEM CELL TRANSPLANTATION; SUICIDE GENE THERAPY; TERATOGENESIS; TUMOR VASCULARIZATION; VIRUS PARTICLE;

BRAIN; BRAIN NEOPLASMS; CYTOKINES; EMBRYONIC STEM CELLS; GENE THERAPY; GLIOMA; HUMANS; MESENCHYMAL STEM CELLS; NEURAL STEM CELLS; PRODRUGS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84859526994     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor204     Document Type: Article

References (97)

1. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci. 2000;97:12846-12851.
2. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cellmediated tumor selective gene therapy. Gene Ther. 2008;15: 739-752. (Pubitemid 351627357)
3. Einstein O, Ben-Hur T. The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol. 2008;65:452-456. (Pubitemid 351549952)
4. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol. 2008;36:733-741. (Pubitemid 351636190)
5. English K, Wood KJ. Immunogenicity of embryonic stem cell-derived progenitors after transplantation. Curr Opin Organ Transplant. 2011;16:90-95.
6. Germano IM, Binello E. Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol. 2009;93:79-87.
7. Central Brain Tumor Registry of the United States. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2010.
8. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
9. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
10. Germano IM, Swiss V, Casaccia P. Primary brain tumors, neural stem cells, and brain tumor cancer cells: where is the link? Neuropharmacol. 2010;58:903-910.
11. Picinich SC, Mishra PJ, Glod J, et al. The therapeutic potential of mesenchymal stem cells. Expert Opin Biol. 2007;7:965-973. (Pubitemid 47204355)
12. Germano IM, Uzzaman M, Keller G. Gene delivery by embryonic stem cells for malignant glioma therapy: hype or hope? Cancer Biol Ther. 2008;7:1341-1347.
13. deVries NA, Beijnen JH, van Tellingen O. High-grade glioma mouse models and their applicability for pre-clinical testing. Cancer Treat Rev. 2009;31:714-723.
14. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006;12: 5288-5297. (Pubitemid 44497241)
15. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 2005;19:1129-1155. (Pubitemid 40696181)
16. Das S, Bonaguidi M, Muro K, et al. Generation of embryonic stem cells: limitations of and alternatives to inner cell harvest. Neurosurg Focus. 2008;24:E3.
17. Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7:20-24.
18. Benveniste RJ, Keller G, Germano IM. Embryonic stem cell-derived astrocytes expressing drug-inducible transgenes: differentiation and transplantation into the mouse brain. J Neurosurg. 2005;103:115-123. (Pubitemid 43193943)
19. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M. Role of astrocytes in brain function and disease. Toxicol Pathol. 2011;39:115-123.
20. Uzzaman M, Benveniste RJ, Keller G, et al. Embryonic stem cell-derived astrocytes: a novel gene therapy vector for brain tumors. Neurosurg Focus. 2005;19:E6.
21. Germano IM, Uzzaman M, Benveniste RJ, et al. Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrcoytes expressing tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 2006;105:88-95. (Pubitemid 43979102)
22. Uzzaman M, Keller G, Germano IM. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J Neurosurg. 2007;106:646-651. (Pubitemid 46536462)
23. Uzzaman M, Keller G, Germano IM. In vivo gene delivery by embryonic stem cell-derived astrocytes for malignant gliomas. Neurooncol. 2009;11:102-108.
24. Germano IM, Emdad L, Qadeer ZA, et al. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. Cancer Gene Ther. 2010;17:664-674.
25. Emdad L, Lebedeva IV, Su ZZ, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther. 2009;8:391-400.
26. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nature Med. 2000;6:447-450. (Pubitemid 30208163)
27. Ehtesham M, Kabos P, Kabosova A, et al. The use of interleukin-12- secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 2002;62:5657-5663. (Pubitemid 35204717)
28. Yuan X, Hu J, Belladonna ML, et al. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 2006;66:2630-2638.
29. Ehtesham M, Kabos P, Gutierrez MAR, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002;62: 7170-7174. (Pubitemid 36025232)
30. Balyasnikova I, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 2011;310:148-159.
31. Shah K, Tung CH, Yang K, et al. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res. 2004;64:3236-3242. (Pubitemid 38581428)
32. Shah K, Bureau E, Kim DE, et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol. 2005;57:34-41. (Pubitemid 40053313)
33. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther. 2004;10:1071-1084. (Pubitemid 39625251)
34. Corsten MF, Miranda R, Kasmieh R, et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas. Cancer Res. 2007;67:8994-9000. (Pubitemid 47535880)
35. Hingten S, Ren X, Terwilliger E, et al. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and temozolomide. Mol Cancer Ther. 2008;7:3575-3585.
36. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701-1708.
37. Li S, Tokuyama T, Yamamoto J, et al. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther. 2005;12:600-607. (Pubitemid 40967220)
38. Li S, Tokuyama T, Yamamoto J, et al. Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncol. 2005;69:503-508.
39. Li S, Gao Y, Tokuyama T, et al. Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett. 2007;251:220-227. (Pubitemid 46669798)
40. Uhl M, Weiler M, Wick W, et al. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochem Biophys Res Comm. 2005;328:125-129. (Pubitemid 40164644)
41. Barresi V, Belluardo N, Sipione S, et al. Transplantation of prodrugconverting neural progenitor cells for brain tumor therapy. Cancer Gene Ther. 2003;10:396-402. (Pubitemid 36528783)
42. Ichikawa T, Tamiya T, Adachi Y, et al. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther. 2000;7:74-82. (Pubitemid 30080990)
43. Lee DH, Ahm Y, Kim SU, et al. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 2009;15:4925-4934.
44. Ito S, Natsume A, Shimato S, et al. Human neural stem cells transduced with IFN-b and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer Gene Ther. 2010;17:299-306.
45. Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther. 2000;1:347-357.
46. Tyler M, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16:262-278.
47. Ahmed AU, Thaci B, Alexiades N, et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther. 2011;19:1714-1726.
48. Nakashima H, Kaur B, Chiocca EA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev. 2010; 21:119-126.
49. Ahmed AU, Tyler MA, Thaci B, et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm. 2011;8:1559-1572.
50. Bello L, Lucini V, Carrabba G, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion of a naturally occurring fragment of human metalloproteinase-2. Cancer Res. 2001;61:8730-8736. (Pubitemid 34013884)
51. Kim SK, Cargioli TG, Machluf M, et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res. 2005;11:5965-5970. (Pubitemid 41170327)
52. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20:5-14.
53. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2009;11:1155-1164. (Pubitemid 39117311)
54. ThangNNT, Derouazi M, PhilippinG, et al. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res. 2010;70:4829-4839.
55. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65:3307-3318. (Pubitemid 40524615)
56. Sato H, Kuwashima N, Sakaida T, et al. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther. 2005;12:757-768. (Pubitemid 41208615)
57. Xu G, Jiang XD, Xu Y, et al. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int. 2009;33:466-474.
58. Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008;68:9614-9623.
59. Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci. 2009;106:4822-4827.
60. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells. 2009;27:2320-2330.
61. Yang B, Wu X, Mao Y, et al. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factorrelated, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurg. 2009;65:610-624.
62. Ryu CH, Park SH, Park SA, et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther. 2011;22:733-743.
63. Hong X, Miller C, Savant-Bhonsale S, Kalkanis SN. Anti-tumor treatment using interleukin-12-secreting marrow stromal cells in invasive glioma model. Neurosurg. 2009;64:1139-1147.
64. Bagci-Onder T, Wakimoto H, Anderegg M, et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011;71:154-163.
65. Kang SG, Jeun SS, Lim JY, et al. Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. Childs Nerv Sys. 2008;24:293-302. (Pubitemid 351234068)
66. Miletic H, Fischer Y, Litwak S, et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther. 2007;15:1373-1381. (Pubitemid 46965333)
67. Uchibori R, Okada T, Ito T, et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med. 2009;11:373-381.
68. Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26:831-841.
69. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus D24-RGD to human gliomas. Cancer Res. 2009;69: 8932-8940.
70. Toth K, Spencer JF, Tollefson AE, et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther. 2005;16: 139-146. (Pubitemid 40250340)
71. Ahmed AU, Rolle CE, Tyler MA, et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther. 2010;18: 1846-1856.
72. Balyasnikova IV, Franco-Gou R, Mathis JM, et al. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med. 2010;4: 247-258.
73. Balyasnikova IV, Ferguson SD, Sengupta S, et al. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS ONE. 2010;5:e9750.
74. Gan HK, Kaye AH, Luwor R. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16:748-754.
75. Cayre M, Canoll P, Goldman JE. Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol. 2009; 88:41-63.
76. Jin J, Galvan V. Endogenous neural stem cells in the adult brain. J Neuroimmune Pharmacol. 2007;2:236-242.
77. Sanai N, Tramontin AD, Quinones-Hinojosa A, et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature. 2004;427:740-744. (Pubitemid 38294593)
78. Curtis MA, Kam M, Nannmark U, et al. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science. 2007;315:1243-1249. (Pubitemid 46364256)
79. Sanai N, Garcia-Verdugo JM, Alvarez-Buylla A. Comment on "Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension". Science. 2007;318:393.
80. Amariglio N, Hirschberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an Ataxia Telangiectasia patient. PLoS Med. 2009;6:e1000029.
81. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133-158. (Pubitemid 351932182)
82. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrowderived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142-9149. (Pubitemid 47535900)
83. Røsland GR, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009;69: 5331-5339.
84. Torsvik A, Røsland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects crosscontamination: putting the research field on track-letter. Cancer Res. 2010;70:6393-6396.
85. Master Z, McLeod M, Mendez I. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. J Med Ethics. 2007;33:169-173.
86. Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Experiment Gerontol. 2008;43:1018-1023.
87. Zarzecny A, Caulfield T. Emerging ethical, legal and social issues associated with stem cell research and the current role of the moral status of the embryo. Stem Cell Rev and Rep. 2009;5:96-101.
88. Brown M. No ethical bypass of moral status in stem cell research. Bioethics. 2011 doi:10.1111/j.1467-8519.2011.01891.x.
89. Selden NR, Guillame DJ, Huhn SL, Koch TK, Al-Uzri A, Steiner RD. CNS transplantation of purified human neural stem cells in neuronal ceroid lipofuscinoses: phase I trial. American Association of Neurological Surgeons, Annual Meeting, Philadelphia, May 1-5, 2010 Abstract #600.
90. http://www.clinicaltrials.gov/ct2/show/NCT00337636?term=NCT003 37636&rank=1. Accessed October 16, 2011.
91. http://www.clinicaltrials.gov/ct2/show/NCT01348451?term=NCT0134 8451&rank=1. Accessed October 16, 2011.
92. Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011;134:1790-1807.
93. Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis. 2010;16:503-510.
94. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone marrow transplant. 2002;30:215-222. (Pubitemid 35023593)
95. Najbauer J, Danks MK, Kim SU, et al. Neural stem cell mediated tumorselective gene delivery: towards high grade glioma clinical trials. Mol Ther. 2008;16(Supplement 1):S136.
96. http://www.clinicaltrials.gov/ct2/show/NCT01172964?term=NCT0117 2964&rank=1. Accessed October 16, 2011.
97. Piccirillo SGM, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761-765. (Pubitemid 44949605)